Golden-ADC (101158064)

  https://cordis.europa.eu/project/id/101158064

  Horizon Europe (2021-2027)

  An Insulin-Gold Nanoplatform as Enhanced Antibody-Drug Conjugate Cancer Therapy

  ERC PROOF OF CONCEPT GRANTS (ERC-2023-POC)

  breast cancer  ·  pharmacokinetics  ·  nano-materials

  2024-03-01 Start Date (YY-MM-DD)

  2025-08-31 End Date (YY-MM-DD)

  € 0

  Description

Antibody-drug conjugates (ADCs) have emerged as promising therapies by combining the precision targeting abilities of antibodies with the potency of chemotherapy drugs, to directly attack cancer cells and minimize damage to healthy tissue. However, approved ADCs show low efficacies in treating solid tumours, due to inherent challenges. These include design challenges, which limit the drug-antibody ratio and the ability to integrate multiple drug types, and delivery challenges, in which pharmacokinetics and tumor barriers limit ADC accumulation and distribution within tumours. In the framework of the ERC-CoG project, we are developing gold nanoparticles (GNPs) that harness insulin for delivery of large therapeutics, including antibodies, across biological barriers. As part of this research, we have recently revealed that these insulin-GNPs can be further developed as an ADC nanoplatform. This Golden-ADC nanoplatform enables simple conjugation of large payloads of multiple antibodies and drug types, shows efficacy in cancer cell models, and enhances in vivo tumor accumulation, together with deep penetration and wide distribution throughout the tumour. In this PoC proposal, we will test our Golden-ADC nanoplatform for effective and safe treatment of triple negative breast cancer, due to the potential high benefits that our nanoplatform can provide for this hard-to-treat cancer, which has a long-standing paucity of effective therapies. Within GOLDEN ADC, we aim to acheive significant progress in the technology development process, by proof of concept demonstration of efficacy and safety of the Golden-ADC conjugated with multiple drugs in in-vivo triple negative breast cancer models. We also intend to achieve business readiness, via consolidating the IP strategy, undertaking a comprehensive market analysis, end-user engagement and developing the business strategy.

  Complicit Organisations

1 Israeli organisation participates in Golden-ADC.